Clinical trials: Metastatic Castration-resistant Prostate Cancer, mCRPC
- Condition Metastatic Castration-resistant Prostate Cancer, mCRPC
- Funder type Industry (pharma, biotech, devices)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- ProvONE (NCT06134232)
- Testing
- Sipuleucel-T Injection
- Where
- 31 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dendreon
Prostate Cancer
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen…
- Trial name
- VISION (NCT03511664)
- Testing
- 177Lu-PSMA-617, Best supportive/best standard of care
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 861 people
- Sponsor
- Endocyte
Metastatic Castration Resistant Prostate Cancer
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy.
- Trial name
- NCT04634344
- Testing
- DZD2269
- Where
- 6 sites in United States, South Korea
- Volunteers
- 16 people
- Sponsor
- Dizal Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment…
- Trial name
- TRITON3 (NCT02975934)
- Testing
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Where
- 150 sites in United States, Australia and 10 more
- Volunteers
- 405 people
- Sponsor
- pharmaand GmbH
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Metastatic Castration Resistant Prostate Cancer
A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04615845
- Testing
- Cellgram-DC-PC
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- Pharmicell Co., Ltd.
Prostate Cancer
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel…
- Trial name
- CAPItello280 (NCT05348577)
- Testing
- capivasertib, docetaxel
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
- Trial name
- NCT06383052
- Testing
- 177Lu-NYM032 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Norroy Bioscience Co., LTD
Hormone-refractory Prostate Cancer
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment.
- Trial name
- NCT05997615
- Testing
- VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer, mCRPC
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of…
- Trial name
- NCT05547061
- Testing
- Lu-177-DGUL, Ga-68-NGUL
- Where
- 4 sites in South Korea
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Cellbion Co., Ltd.
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant…
- Trial name
- NCT03792841
- Testing
- acapatamab, Pembrolizumab, Etanercept
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 212 people
- Sponsor
- Amgen
Neoplasms
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta)…
- Trial name
- NCT02215096
- Testing
- GSK2636771, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Metastatic Castration Resistant Prostate Cancer
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study.
- Trial name
- NCT06866795
- Testing
- GT-220F capsule
- Volunteers
- 42 people
- Sponsor
- Geode Therapeutics Inc.
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Advanced Solid Tumor, HER2-negative Breast Cancer
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
- Trial name
- NCT06334432
- Testing
- NUV-1511
- Where
- 8 sites in United States
- Volunteers
- 466 people
- Sponsor
- Nuvation Bio Inc.
Neoplasms, Prostate
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
- Trial name
- NCT07332455
- Testing
- GSK5471713
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Metastatic Castration-resistant Prostate Cancer, mCRPC
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
100 mCi of [177Lu]Ludotadipep, the dose determined in the phase 1 clinical trial (FC705-1), was administered repeatedly up to 6 times at intervals of 8 weeks (±2 weeks) to patients with metastatic castration resistant prostate…
- Trial name
- LUCIDA_2 (NCT05579184)
- Testing
- [177Lu]Ludotadipep
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- FutureChem
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT05171816
- Testing
- olaparib, abiraterone acetate
- Where
- 26 sites in China
- Volunteers
- 110 people
- Sponsor
- AstraZeneca
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
Primary Objective: To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m^2) plus prednisone (Arm A) versus either enzalutamide at 160…
- Trial name
- PRIMCAB (NCT02379390)
- Testing
- Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate
- Where
- 24 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Sanofi
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and…
- Trial name
- RADIANT (NCT04597125)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), ARPI therapy
- Where
- 117 sites in Australia, Austria and 17 more
- Volunteers
- 654 people
- Sponsor
- Bayer